• If you are wondering whether Guardian Pharmacy Services at US$37.37 still offers value after a strong run, the next sections will walk through what the current price could be implying.
• The stock has slipped 0.5% over the last 7 days and 1.6% over the last 30 days, yet it is still up 26.5% year to date and 44.9% over the past year, which may have shifted how some investors view its risk and reward trade off.
• Recent attention on Guardian Pharmacy Services has largely centered on its role within the healthcare sector and how investors are framing its long term prospects, which helps explain why the share price has remained in focus despite short term moves. Coverage has highlighted how market participants are weighing the durability of its business model and what they are willing to pay for that exposure.
• Against this backdrop, Guardian Pharmacy Services currently holds a valuation score of 1 out of 6. The sections ahead will compare different valuation methods while also pointing to a more complete way to think about what this price really means.

Guardian Pharmacy Services scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Guardian Pharmacy Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth today by projecting its future cash flows and discounting them back to a present value.

For Guardian Pharmacy Services, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $80.6 million. Looking ahead, analyst and extrapolated estimates indicate free cash flow of $77.3 million in 2026 and $105.2 million in 2035, with interim years gradually stepping up according to Simply Wall St’s projections.

When these projected cash flows are discounted back, the DCF model suggests an estimated intrinsic value of about $34.43 per share. With the current share price at US$37.37, the model indicates the stock is around 8.5% above this estimate, which is a relatively modest gap.

Result: ABOUT RIGHT

Guardian Pharmacy Services is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Guardian Pharmacy Services Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings, which makes it a common anchor for comparing stocks within the same sector.

What counts as a “normal” P/E usually reflects how the market views a company’s growth potential and risk. Higher expected growth and lower perceived risk can support a higher P/E, while slower growth or higher uncertainty often justify a lower one.

Guardian Pharmacy Services currently trades on a P/E of 48.1x. That sits close to both the peer average of 48.5x and the broader Healthcare sector average of about 24.9x. Simply Wall St’s Fair Ratio for Guardian Pharmacy Services is 25.2x. This Fair Ratio is a proprietary estimate of what the P/E could be, given factors such as earnings growth, profit margins, industry, market cap and company specific risks.

Because the Fair Ratio adjusts for these business fundamentals, it can be more tailored than a simple comparison with peers or the sector alone. With the current P/E of 48.1x versus a Fair Ratio of 25.2x, the shares screen as expensive on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Guardian Pharmacy Services Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Guardian Pharmacy Services into a clear story that links its business context to a set of revenue, earnings and margin forecasts, rolls those into a Fair Value you can compare with the current price to help you decide whether to buy or sell, and then keeps that view updated as new news or earnings arrive. This is why one investor might build a higher value Narrative that leans on expectations like earnings of up to $102.1 million and a P/E of 30.5x by 2028, while another might choose a lower value Narrative closer to $67.7 million in earnings using the same Community tools on the platform.

Do you think there's more to the story for Guardian Pharmacy Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.